|
A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China |
Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S |
|
|
Record Status This is an economic evaluation that meets the criteria for inclusion on NHS EED. Bibliographic details Yu YF, Chen ZW, Zhou Z, Song ZB, Li ZM, Jian H, Zhang YF, Lu S. A cost-effectiveness analysis of docetaxel versus pemetrexed in second-line chemotherapy for stage IIIb or IV non-small cell lung cancer in China. Chemotherapy 2010; 56(6): 472-477 Indexing Status Subject indexing assigned by NLM MeSH Antineoplastic Agents /adverse effects /therapeutic use; Antineoplastic Combined Chemotherapy Protocols /adverse effects /therapeutic use; Carcinoma, Non-Small-Cell Lung /drug therapy /mortality /pathology; Cost-Benefit Analysis; Disease-Free Survival; Glutamates /adverse effects /therapeutic use; Guanine /adverse effects /analogs & Humans; Lung Neoplasms /drug therapy /mortality /pathology; Neoplasm Recurrence, Local /drug therapy; Neoplasm Staging; Pemetrexed; Platinum Compounds /therapeutic use; Retrospective Studies; Taxoids /adverse effects /therapeutic use; derivatives /therapeutic use AccessionNumber 22011000264 Date bibliographic record published 06/04/2011 |
|
|
|